Protein-Tyrosine Kinases

"Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.

Descriptor ID	D011505
MeSH Number(s)	D08.811.913.696.620.682.725
Concept/Terms	Protein-Tyrosine Kinases Protein-Tyrosine Kinases Kinases, Protein-Tyrosine Protein Tyrosine Kinases Tyrosine Kinase Kinase, Tyrosine Tyrosine Protein Kinase Kinase, Tyrosine Protein Tyrosylprotein Kinase Kinase, Tyrosylprotein Tyrosine-Specific Protein Kinase Kinase, Tyrosine-Specific Protein Protein Kinase, Tyrosine-Specific Tyrosine Specific Protein Kinase Tyrosine-Specific Protein Kinases Kinases, Tyrosine-Specific Protein Protein Kinases, Tyrosine-Specific Tyrosine Specific Protein Kinases Protein-Tyrosine Kinase Kinase, Protein-Tyrosine Protein Tyrosine Kinase Tyrosine Protein Kinases Kinases, Tyrosine Protein Protein Kinases, Tyrosine

Below are MeSH descriptors whose meaning is more general than "Protein-Tyrosine Kinases".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]

Below are MeSH descriptors whose meaning is related to "Protein-Tyrosine Kinases".

Below are MeSH descriptors whose meaning is more specific than "Protein-Tyrosine Kinases".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Protein-Tyrosine Kinases" by people in this website by year, and whether "Protein-Tyrosine Kinases" was a major or minor topic of these publications.

Bar chart showing 884 publications over 31 distinct years, with a maximum of 55 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	13	6	19
1993	15	3	18
1994	12	4	16
1995	13	13	26
1996	15	6	21
1997	11	11	22
1998	15	8	23
1999	14	9	23
2000	8	10	18
2001	22	10	32
2002	21	24	45
2003	20	35	55
2004	19	31	50
2005	29	22	51
2006	25	24	49
2007	21	22	43
2008	20	11	31
2009	15	18	33
2010	26	13	39
2011	30	18	48
2012	21	15	36
2013	21	11	32
2014	18	5	23
2015	22	12	34
2016	13	11	24
2017	12	15	27
2018	7	3	10
2019	7	5	12
2020	6	7	13
2021	7	3	10
2022	0	1	1

Below are the most recent publications written about "Protein-Tyrosine Kinases" by people in Profiles.

Robert NJ, Espirito JL, Chen L, Nwokeji E, Karhade M, Evangelist M, Spira A, Neubauer M, Bullock S, Walberg J, Cheng SK, Coleman RL. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network. Lung Cancer. 2022 04; 166:197-204.

View in: PubMed
Li Y, Xie X, Jie Z, Zhu L, Yang JY, Ko CJ, Gao T, Jain A, Jung SY, Baran N, Konopleva MY, Cheng X, Sun SC. DYRK1a mediates BAFF-induced noncanonical NF-?B activation to promote autoimmunity and B-cell leukemogenesis. Blood. 2021 12 09; 138(23):2360-2371.

View in: PubMed
Guo E, Xiao R, Wu Y, Lu F, Liu C, Yang B, Li X, Fu Y, Wang Z, Li Y, Huang Y, Li F, Wu X, You L, Qin T, Lu Y, Huang X, Ma D, Mills GB, Sun C, Chen G. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. J Exp Med. 2022 01 03; 219(1).

View in: PubMed
Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica. 2021 11 01; 106(11):2853-2858.

View in: PubMed
Xu H, George E, Kinose Y, Kim H, Shah JB, Peake JD, Ferman B, Medvedev S, Murtha T, Barger CJ, Devins KM, D'Andrea K, Wubbenhorst B, Schwartz LE, Hwang WT, Mills GB, Nathanson KL, Karpf AR, Drapkin R, Brown EJ, Simpkins F. CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Rep Med. 2021 09 21; 2(9):100394.

View in: PubMed
Ramagopalan S, Leahy TP, Ray J, Wilkinson S, Sammon C, Subbiah V. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Med. 2021 09 15; 19(1):209.

View in: PubMed
Lindemann A, Patel AA, Tang L, Tanaka N, Gleber-Netto FO, Bartels MD, Wang L, McGrail DJ, Lin SY, Frank SJ, Frederick MJ, Myers JN, Osman AA. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Mol Cancer Ther. 2021 07; 20(7):1257-1269.

View in: PubMed
Packard A, Klein WH, Costantini F. Ret signaling in ureteric bud epithelial cells controls cell movements, cell clustering and bud formation. Development. 2021 05 01; 148(9).

View in: PubMed
Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PA. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.

View in: PubMed
Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med. 2021 04; 10(7):2341-2349.

View in: PubMed

People

Explore

Similar Concepts

Top Journals